Next, we evaluated the correlation between pIGF-1R expression and the clinical efficacy of osimertinib administered as the first-line treatment in 16 patients with AXL-low (no to 1+) expressing EGFR-mutated NSCLC. Here, AXL is linked to non-small cell lung carcinoma.